Almirall, S.A. announced that a key milestone under the collaboration with Nuevolution has been achieved. The strategic collaboration was entered on December 12, 2016 with the aim to develop innovative RORγt inhibitors with best-in-class potential for the oral and topical treatment of dermatology diseases and psoriatic arthritis. A significant part of the collaboration work has been to evaluate pre-clinical safety parameters of RORγt inhibition and to comprehensively de-risk the program prior to any human testing. The milestone data achieved supports a program with a Candidate Drug (CD) having best-in-class potential.
The program continues its progression towards clinical development. The positive result triggered a contractual milestone to Nuevolution.
Bhushan Hardas, M.D., MBA, chief scientific officer of Almirall, commented, “We are very pleased with the progress achieved in our strategic collaboration with Nuevolution, which reflects Almirall’s commitment to becoming a leader in medical dermatology by reinforcing our pipeline with true innovative best in class solutions.”
Alex H. Gouliaev, Ph.D., chief executive officer of Nuevolution, commented, “This underscores the positive opportunities for this unique program. The program development has benefitted significantly from much synergy between and dedication by the teams.”
Almirall had one of the highest levels of research and development investments in the Spanish pharmaceutical industry in 2018, representing over 12 percent of net sales. In addition, Almirall invests in assets, strategic partnerships, and collaborations in research.